Clinical Infectious Diseases

Papers
(The H4-Index of Clinical Infectious Diseases is 71. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
In the Literature443
Educational Impact of #IDJClub, a Twitter-Based Infectious Diseases Journal Club439
Reply to Focosi et al391
Correction to: Impact of Point-of-Care Testing on the Management of Sexually Transmitted Infections in South Africa: Evidence from the HVTN702 Human Immunodeficiency Virus Vaccine Trial384
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission Associated With an Indoor Music Event That Required Proof of Full Vaccination Against Coronavirus Disease 2019 (COVID-19) Prio378
Executive Summary: State-of-the-Art Review: State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative Organisms372
Withdrawn as duplicate: Cover image/text324
Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines: Perceptions and Attitudes From the Food and Drug Administration Public Commentary269
Population Mobility and Aging Accelerate the Transmission of Coronavirus Disease 2019 in the Deep South: A County-Level Longitudinal Analysis249
Go V.I.R.A.L.: Social Media Engagement Strategies in Infectious Diseases234
Association of Virus Variation and Vaccination Status With Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection217
T-SPOT.TB Reactivity in Southern African Children With and Without in Utero Human Immunodeficiency Virus Exposure169
Is Inhaled Zanamivir Non-inferior to Oral Oseltamivir in the Treatment of Outpatients With Influenza?162
Transmission of Mycobacterium tuberculosis to Healthcare Personnel Resulting From Contaminated Bone Graft Material, United States, June 2021–August 2022160
Response to Rezahosseini and Barrella Harboe146
Corrigendum to: A New Specimen for Syphilis Diagnosis: Evidence by High Loads ofTreponema pallidumDNA in Saliva129
Case Investigation and Contact Tracing Efforts From Health Departments in the United States, November 2020 to December 2021128
Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 201127
Eyes Wide Shut: A Cohort Study Questioning the Role of Fundoscopy in Infective Endocarditis Diagnosis122
Validation of ISARIC 4C Mortality and Deterioration Scores in a Mixed Vaccination Status Cohort of Hospitalized Coronavirus Disease 2019 (COVID-19) Patients in Singapore122
Use of Carbon Dioxide Monitoring to Assess Ventilation at a National Infectious Diseases Conference118
Susceptibility to Human Immunodeficiency Virus Type 1 Acquisition Linked to Malaria Exposure: A Case-Control Study113
Integrating Human Immunodeficiency Virus–Specific Elements in the Treatment of Tobacco Dependence (ANRS 144 Inter-ACTIV)112
Correction to: Severe Dysbiosis and Specific Haemophilus and Neisseria Signatures as Hallmarks of the Oropharyngeal Microbiome in Critically Ill Coronavirus Disease 2019 (COVID-19) Patie112
Effectiveness of a Second Dose of an mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in Individuals Previously Infected by Other Variants111
Response to ‘Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome’109
Comparison of Hospitalized Coronavirus Disease 2019 and Influenza Patients Requiring Supplemental Oxygen in a Cohort Study: Clinical Impact and Resource Consumption107
Viral Suppression Trajectories Destabilized After Coronavirus Disease 2019 Among US People With Human Immunodeficiency Virus: An Interrupted Time Series Analysis106
Development of an Effective Immune Response in Adults With Down Syndrome After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination103
Systematic Review of In Vitro Antimicrobial Susceptibility Testing for Bacillus anthracis, 1947–2019101
Correction to: Prevalence of Ocular Complications in Candidemia: Defining the “Battlefield”101
Accelerating Progress Towards the 2030 Neglected Tropical Diseases Targets: How Can Quantitative Modeling Support Programmatic Decisions?98
Crude Mortality Associated With the Empirical Use of Polymyxins in Septic Patients in a Setting of High Prevalence of Carbapenem-Resistant Gram-negative Bacteria: Retrospective Analysis of a Cohort97
Pre-exposure Prophylaxis for Transgender People: A Systematic Review96
Correction to: Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Val96
Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment95
COVID-19 Antiviral Medication Use Among Pregnant and Recently Pregnant US Outpatients94
Epigenetic Age Acceleration Markers Are Associated With Physiologic Frailty and All-Cause Mortality in People With Human Immunodeficiency Virus93
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection by Intranasal or Intratesticular Route Induces Testicular Damage93
Post-artesunate Delayed Hemolysis in Patients With Severe Malaria in the United States—April 2019 Through July 202191
Point-of-care Ultrasound in Infectious Diseases: Current Insights and Future Perspectives90
Circulation of Third-Generation Cephalosporin Resistant Salmonella Typhi in Mumbai, India89
How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus–Associated Cryptococcal Meningitis to High-Income Settings?89
The Urgent Need to Implement Point-of-Care RNA Testing for Hepatitis C Virus to Support Elimination88
Superiority Trials in Invasive Aspergillosis: A Harsh Reality Check With the IA-DUET (HOVON502) Trial85
Development of a Machine Learning Modeling Tool for Predicting HIV Incidence Using Public Health Data From a County in the Southern United States85
Considerations on the Associations Between Antiretroviral Regimen and Changes in Blood Pressure in the D2EFT Study83
Correction to: Clinical Experience With Severe Acute Respiratory Syndrome Coronavirus 2–Related Illness in Children: Hospital Experience in Cape Town, South Africa81
Influenza Hospitalization Burden by Subtype, Age, Comorbidity, and Vaccination Status: 2012–2013 to 2018–2019 Seasons, Quebec, Canada81
Comparative Effectiveness of BNT162b2 and mRNA-1273 Booster Dose After BNT162b2 Primary Vaccination Against the Omicron Variants: A Retrospective Cohort Study Using Large-Scale Population-Based Regist80
Acute Appendicitis of Unexpected Etiology80
Does “Toxoplasma Abscess” Properly Describe Brain Lesions Caused by Toxoplasma gondii?80
Modeling Respiratory Syncytial Virus Adult Vaccination in the United States With a Dynamic Transmission Model80
Daily Second-generation Integrase Strand Inhibitors and Short-course Tuberculosis Preventive Therapy: What More Do We Need to Know?79
Diagnostic Uncertainties and Delayed Treatment Protocols Impact Efficacy of FMT for C. Difficile Infection78
Revisiting REVISIT: The Case for Ceftazidime/Avibactam Plus Aztreonam77
A Point-of-Care Prediction Tool for Recurrent Tuberculosis76
Remdesivir Effectiveness in Reducing the Risk of 30-Day Readmission in Vulnerable Patients Hospitalized for COVID-19: A Retrospective US Cohort Study Using Propensity Scores76
Redefining Complicated Coagulase-Negative Staphylococcal Bacteremia76
Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C76
Comparative Performance of Urine Lipoarabinomannan and Urine Xpert MTB/RIF Ultra for Diagnosing Tuberculosis in Adult Inpatients With Human Immunodeficiency Virus in East London, South Africa76
Don’t Put Off Until Tomorrow What You Can Do Today: Hospital Admissions as an Opportunity to Treat Hepatitis C75
Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial75
CD4/CD8 Ratio During Human Immunodeficiency Virus Treatment: Time for Routine Monitoring?74
Medicare Prescription Plans Limit Access to Recommended Drugs for Clostridioides difficile Infection74
Impact of Vaccination and Early Monoclonal Antibody Therapy on Coronavirus Disease 2019 Outcomes in Organ Transplant Recipients During the Omicron Wave74
A National Retrospective Cohort Study Comparing the Effects of Cefepime Versus Piperacillin-Tazobactam on the Development of Severe Acute Kidney Injury in Patients With Septic Shock74
Characterizing the Rise of Disseminated Gonococcal Infections in California, July 2020–July 202174
Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States73
Reduced Odds of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Vaccination Among New York City Adults, July 2021–November 202173
Mass Drug Administration for the Control of Scabies: A Systematic Review and Meta-analysis72
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Ill71
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial71
A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptas71
0.19696617126465